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Abstract
Background: Plasma adiponectin is a significant correlate of the pro-inflammatory cardiometabolic risk profile
associated with obesity and type 2 diabetes. Salivary pH is influenced by several cardiometabolic risk components
such as inflammation, oxidation and numerous oral and systemic health modulators, including the menopausal
status. This study aimed to assess the association between plasma adiponectin concentrations and salivary pH in
women according to the menopausal status.
Method: Unstimulated saliva collection was performed in 151 Caucasian women of French-Canadian origin (53
premenopausal women (PMW) and 98 menopausal women (MW)). Student’s t test, ANOVA and linear regression
models were used to assess the association between plasma adiponectin concentrations and salivary pH.
Results: Plasma adiponectin levels increased as a function of salivary pH in the whole sample and among MW (r = 0.29
and r = 0.36, p < 0.001). The proportion of the variance of plasma adiponectin levels explained by the salivary pH (R
2)
was 10.8% (p < 0.001). Plasma adiponectin levels progressively increased across salivary pH quartiles (p = 0.005).
Conclusions: These results suggest that salivary pH is a significant correlate of plasma adiponectin levels in
women. With the increasing prevalence of type 2 diabetes and obesity, new technologies should be developed to
more easily monitor health status, disease onset and progression. Salivary pH, a simple, inexpensive and non-
invasive measure, could be a very promising avenue.
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Introduction
According to the World Health Organization, by 2015
approximately 2.3 billion adults worldwide will be over-
weight and more than 700 million obese [1]. The bur-
den of the associated cardiometabolic risk components,
such as type 2 diabetes mellitus (T2DM), dyslipidemia
and cardiovascular disease (CVD), is also set to grow
rapidly. Not only is this epidemic progression observed
in developed countries, but it increasingly affects devel-
oping countries too. Moreover, it has been estimated
that by 2025, three out of four people with T2DM or
other cardiometabolic risk components will be living in
third world countries [2]. It is therefore mandatory to
develop improved and more accessible screening tools
in order to devise finer preventive and therapeutic
strategies.
Adiponectin has been identified as a new biochemical
marker of visceral fat accumulation and could represent a
critical link between obesity and the cardiometabolic risk
profile [3]. Adiponectin is an adipocyte-derived protein,
highly abundant in plasma, with concentrations ranging
from 5 to 30 μg/ml (0.01% of total plasma) [4]. Its levels
correlate with the development of T2DM [5,6], dyslipide-
mia, hypertension [7] and CVD [8]. Adiponectin may also
have different immune functions in several biological
systems. It exerts anti-inflammatory, insulin-sensitizing and
anti-atherosclerotic effects when secreted into the circula-
tion [9]. Therefore, in the search for indexes of metabolic
perturbations and proinflammatory status predisposing to
a deteriorated cardiometabolic risk profile, the measure-
ment of plasma adiponectin concentrations is increasingly
studied. However, in the context of this epidemic progres-
sion of T2DM and obesity and in order to develop accessi-
ble tools without increasing the burden of healthcare costs,
it is imperative to develop alternatives to the traditional
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the biofluids of the human body, the sampling of saliva is
the most readily available and non-invasive method. It
could thus be an interesting avenue.
Salivary function depends on its flow rate and composi-
tion. A healthy flow rate is critical for the maintenance of
the whole body health. Saliva helps bolus formation by
moistening food, protects the oral mucosa against
mechanical damage, plays a role in preliminary digestion
and has defense functions against pathogen microorgan-
isms [10]. The saliva flow rate is also a modulator of sali-
vary pH. At low flow rates, less bicarbonate is released,
and pH decreases [11]. Salivary flow rates vary widely
between subjects [12]. However, it remains quite constant
during the different stages of life for a given individual. In
fact, low secretors tend to stay in the low range, high
secretors stay in the high range and so on [12]. On aver-
age, women tend to have lower flow rates than men. In
addition, at the individual level, women seem to have
more variation in their salivary pH as well. It has been
suggested that hormonal fluctuations during events like
puberty, menstruation, pregnancy and menopause could
explain those differences [13]. Moreover, there is a notice-
able decrease of unstimulated saliva after menopause [12].
The salivary flow rate is also affected by various cardiome-
tabolic risk components [14]. Degenerative alterations in
the acinar cells, which cause a decrease of the saliva flow
rate and a diminution of salivary pH, are frequently
observed among diabetic and dyslipidemic patients [15].
Hyposalivation has also been linked to obesity, aging and
hypertension [12,16,17].
Interestingly, while the link between plasma glycaemia
and salivary glucose concentrations seems weak, a signifi-
cant correlation has been found between salivary and
plasma adiponectin levels [18,19]. Adiponectin is produced
by salivary gland epithelial cells where it might be impli-
cated in the regulation of the local immune response [20].
Thus adiponectin could help to preserve a good salivary
function and maintain the salivary pH. Besides, consider-
ing the influence of menopause on the salivary flow rate,
this effect could be influenced by the menopausal status.
T h ea i mo ft h i ss t u d yi st h e r e f o r et oa s s e s st h ea s s o -
ciation between salivary pH and plasma adiponectin
concentrations in women according to the menopausal
status.
Methods
Subjects and clinical data
The study comprised a sample of 151 Caucasian women of
French-Canadian origin followed at the Chicoutimi Hospi-
tal Lipid Clinic (Quebec, Canada). Two groups were
formed according to the menopausal status. Postmeno-
pausal status was defined by a self-reported menstrual
status during clinical interviews or was automatically
attributed to all women over 52 years or older at the time
of the interview. The first group is composed of 53 preme-
nopausal women (PMW) and the second group of 98
menopausal women (MW). Anthropometric variables
were measured according to the procedures recommended
by the Airlie Conference [21]. T2DM was diagnosed using
the American Diabetes Association criterion, that is a
2-hour plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during
an oral glucose tolerance test (OGTT). The test was per-
formed as prescribed by the World Health Organization,
using a glucose load containing the equivalent of 75 g
anhydrous glucose dissolved in water (Glucodex
® 75 g)
[22]. The project received the approval of the Chicoutimi
Hospital Ethics Committee, in accordance with the
Declaration of Helsinki.
Biochemical analyses
Blood samples were obtained after a 12-hour overnight fast
from the antecubital vein into vacutainer tubes containing
EDTA. The HDL subfraction was obtained after precipita-
tion of LDL (d > 1.006 g/ml) in the infranatant with
heparin and MnCl2 [23]. Cholesterol, glucose and triglycer-
ide (TG) levels were measured by enzymatic essays on a
Multiparity Analyser CX7 (Beckman, Fullerton, CA, USA).
Fasting plasma adiponectin concentrations were measured
by ELISA (B-bridge International, Inc. San Jose, CA, USA).
The intra- and inter-assay coefficients of variation were
4.00% and 18.98%, respectively. Plasma glycerol concentra-
tions are an important intermediate of glucose and lipid
metabolism. They were measured with an analyzer Techni-
con RA-500 (Bayer Corporation), and enzymatic reagents
were obtained from Randox (Randox Laboratories).
Saliva collection and pH measurement
Although stimulated saliva has generally been taken as
the index of salivary function, the whole unstimulated
saliva collection was chosen for the purpose of this
study because it is the greatest contributor to the total
salivary output [10,12]. All saliva samples were collected
at least 2 hours after any food intake or smoking. Unsti-
mulated saliva was allowed to accumulate in the floor of
the mouth, and the subject then spat it out into a test
tube during 10 minutes. The pH of the saliva sample
was measured with Accumet Basic AB 15 pH Meter
(Ottawa, Canada), and a 13-620-96 Micro pH electrode,
1.5” stem (127 mm) × 3 mm diameter with a pH range
o f0t o1 4( N a +<0 . 1N )a n das e l e c t a b l er e s o l u t i o nt o
0.1, 0.01 or 0.001 pH. The measurements were per-
formed 3 times on each sample with a 0.01 resolution.
The final result is the mean value of the measurements.
Statistical analysis
Due to their skewed distribution, plasma TG, glycerol
and adiponectin levels were log10-transformed before
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in continuous variables we r ec o m p a r e db ye i t h e rt h e
Student’s t test or ANOVA. Categorical variables were
compared using the Pearson c
2. Linear regression mod-
els were constructed in order to investigate the relation-
ship between salivary pH and plasma adiponectin
concentrations, controlling for the effect of covariates
significantly affecting both adiponectin concentrations
and salivary pH. Effects of discrete variables were evalu-
ated dichotomously. The reduced number of subjects in
the study did not enable stratification for medication
but corrections were applied in the different models. All
statistical analyses were performed with the SPSS pack-
age (release 11.0, SPSS, Chicago III).
Results
Subjects’ characteristics are shown in Table 1. Differences
in mean values between PMW and MW reached signifi-
cance level (p < 0.05) for age, waist girth, salivary pH, gly-
cerolemia, plasma TG, adiponectinemia and systolic blood
pressure. Moreover, the percentage of T2DM among MW
was almost twice the one of PMW (p = 0.018).
As shown in Figure 1, plasma adiponectin levels
increased as a function of salivary pH in the whole sam-
ple and among MW (r = 0.29 and r = 0.36, p < 0.001).
Although the correlation did not reach significance level
in PMW, the same trend was observed (r = 0.24; p =
0.086). Plasma adiponectin levels progressively increased
across salivary pH quartiles (p < 0.005) in the whole
sample (Figure 2).
The proportion of the variance of plasma adiponectin
levels explained by the variations of salivary pH (R
2)w a s
10.8% (p < 0.001) in the whole sample (Table 2) and
13.0% (p < 0.001) in the MW (data not shown). The lin-
ear relation between salivary pH and plasma adiponectin
levels remained significant even after including age,
menopausal status, T2DM expression, waist circumfer-
ence and body mass index (BMI) in the multivariate
models (Table 2). When MW were analyzed separately,
the linear relation followed the same trend. Moreover,
these results remained significant even after the inclusion
of hormone replacement therapy and lipid-lowering
medication use to the models (data not shown).
Discussion
In our study, we found that salivary pH is significantly
associated with plasma adiponectin levels in women, parti-
cularly in MW. This association is independent of age,
waist circumference and T2DM. Although numerous stu-
dies have shown correlations between serum and saliva
levels for a wide range of molecular components, none has
studied saliva from this simple perspective [14,24,25].
Alteration in blood adiponectin concentration has been
linked to several metabolic disorders, and a low plasma
level of adiponectin is a significant correlate of the pro-
inflammatory cardiometabolic risk profile [26,27]. Adipo-
nectin is a critical link between visceral adiposity, insulin
resistance and CVD. Among all adipocytokines, it is the
only one with a circulating concentration inversely pro-
portional to adiposity [6]. As with the salivary flow, adipo-
nectin production is inhibited by inflammation and
oxidative stress, while medications used for several cardio-
metabolic risk components are known to increase its levels
[28]. The same pattern is observed in our results. Low adi-
ponectinemia is associated with a low salivary pH. The
decrease of salivary pH could be due to a decrease in the
salivary flow rate that may be associated with systemic
inflammation. Alterations in saliva composition or flow
rate may reflect secondary systemic changes related to dis-
eases, medications or treatments. Those conditions may
trigger an inflammatory status by dysregulation of the
cytokine profile [29]. Interestingly, our results remain sig-
nificant even after the inclusion of the diabetic status in
the model. Diabetes is known to be associated with both
adiponectin levels and salivary pH [16,27,30]. Diabetes is
the most frequent metabolic disease associated with sali-
vary hypofunction and thus with a decreased salivary pH
[16]. Although the causal relationship remains unknown,
many explanations have been proposed. It may be related
to alterations in the major salivary glands similar to
changes observed in the pancreas [14], or linked to auto-
nomic neuropathies triggering a diminished response to







Age (years) 47.9 ± 7.2 64.8 ± 7.6 < 0.001
BMI (kg/m
2) 27.6 ± 5.6 29.3 ± 5.6 0.083
Waist girth (cm) 89.5 ± 12.6 94.9 ± 13.3 0.018
Salivary pH 6.63 ± 0.33 6.76 ± 0.32 0.017
Glycemia(mmol/L) 5.68 ± 2.11 6.04 ± 1.85 NS
Glycerol (mmol/L) * 0.07 ± 0.07 0.11 ± 0.05 < 0.001
TC (mmol/L) 5.78 ± 1.41 6.16 ± 1.14 0.072
HDL-C (mmol/L) 1.37 ± 0.49 1.40 ± 0.34 NS
LDL-C(mmol/L)
a 3.76 ± 1.03 3.69 ± 0.86 NS
TG (mmol/L) * 1.35 ± 3.93 1.90 ± 3.15 0.005
Adiponectin (μg/m) * 6.22 ± 4.54 7.69 ± 4.66 0.027
Systolic BP 121.09 ± 17.37 133.61 ± 16.73 < 0.001
Diastolic BP 74.15 ± 8.84 72.77 ± 9.07 NS
Type 2 diabetes (%)** 22.6 41.8 0.018
Abbreviations: BMI: body mass index; TC: total cholesterol; HDL-C: high-density
lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG:
triglycerides; BP: Blood pressure. Mean ± SD. NS: p > 0.1
a n = 143
*P-values have been obtained after the log10-transpormation of the data.
Geometric means are shown.
** c-2 value
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often occurs in diabetic individuals [30]. The systemic
inflammatory state has also been mentioned as a possible
cause of hyposalivation in T2DM.
The plasma adiponectin level is influenced by a lot of
variables and the numerous interactions between them.
In this context, most of these variables account for only a
small proportion of adiponectin variance so that their
clinical impact may seem small when taken separately.
However, when they are taken together, the proportion
can rapidly rise. Although modest, the observed relation-
ship between salivary pH and adiponectin could therefore
be significant especially since the relationship between
adiponectin and salivary pH remains significant even
when other known covariables are included in the model.
Our study has some limitations. Although the cross-sec-
tional nature of the study takes into account with great
accuracy the metabolic conditions present before the eva-
luation of salivary pH and plasma adiponectin levels, pre-
vious conditions, like insulin resistance or hyperlipidemia,
could have influenced their association. Indeed, the altera-
tions of salivary glands, which may occur following dyslipi-
demia or diabetes, should be assessed in order to exclude
any permanent deficiency or lesion of the acini. Another
limitation is selection bias since participants were
recruited among lipid clinic patients. This could have led
to a higher prevalence of metabolic syndrome related
components such as T2DM. Before any conclusion can be
drawn about the use of salivary pH as a marker of meta-
bolic disturbances, it is mandatory to reproduce these
analyses in men and other populations with different phe-
notypes. Finally, the study does not give any information
about the potential causal pathway that may be implicated.
Since the salivary flow rate and pH remain relatively con-
stant for a given individual during the different stages of
life, salivary gland hypofunction is more commonly asso-
ciated with concomitant diseases or daily use of drugs.
Therefore, a study design with pre- and post-treatment
analyses would add a lot of complementary data to the
present study.
Despite these limitations, our study emphasized the
important association between systemic and oral health.
The results show that variations in salivary pH could pro-
vide a marker of metabolic dysregulation and may be
associated with several elements of the cardiometabolic
risk profile. The measurement of salivary pH does not
need substantial professional and material resources, can
be performed in any clinical setting and is inexpensive. It
therefore opens the door to the development of an acces-
sible screening tool for both developed and developing
countries. Other components within saliva may provide
additional clues on systemic health conditions. Besides,
the development of new technologies may promote a
wider use of salivary assays in the near future. The lower
level of analytes is not a limitation anymore, because the
salivary measurement of small molecules, such as pep-
tides and cytokines, is now feasible. Moreover, there are
compelling reasons to use saliva to monitor health and
diseases. Saliva sampling is an inexpensive, non-invasive
and easy-to-use method. The new, sensitive techniques
Figure 1 a) Association between plasma adiponectin levels and salivary pH in the whole sample, adjusting for age; b) Association
between plasma adiponectin levels and salivary pH in premenopausal women and menopausal women, adjusting for age.
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N=                37                 40                 36                 38 
Range:   [5.61-6.49]   [6.50-6.71]  [6.72-6.92]  [6.93-7.44]  
p=0.005 
Figure 2 Mean plasma adiponectin levels across quartiles of salivary pH in the whole sample, taking into account the effect of age.
Table 2 Linear regression analyses between salivary PH and plasma adiponectin levels in the whole sample
Model 1 Model 2* Model 3* Model 4* Model 5* Model 6*
R
2 10.8 11.8 12.3 24.4 25.3 27.2
p-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Salivary pH
p-value < 0.001 0.001 0.001 0.003 0.003 0.002
Menopause
p-value 0.404 0.405 0.337 0.208
Type 2 diabetes





* Including age as covariate
Dependent variable: Log10 of adiponectin
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ease onset and progression [25,31]. The evaluation of
biomarker levels of T2DM and CVD could be performed
directly from oral fluids, eliminating the need for blood
sampling. Thereby the burden of healthcare costs could
be reduced while increasing the accessibility to screening
tools. However, much work needs to be done in identify-
ing definitive, disease-associated salivary biomarkers.
Many studies should validate the saliva-based test before
it can be used for diagnosis applications.
Conclusion
Saliva is still little used compared to plasma although
it offers several opportunities in diagnostic and moni-
toring. With the emerging worldwide epidemic of
T2DM, obesity and associated disorders, new technolo-
gies should be developed to more easily monitor health
status, disease onset and progression. New accessible
biomarkers that could be readily included in an inte-
grated screening approach, with other non-invasive
and accessible markers, should be identified. In this
context, we think that salivary pH could be a very pro-
mising avenue.
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